[Skip to Content]
[Skip to Content Landing]
April 10, 2013

Bone Marrow–Derived Cell Therapy After Myocardial Infarction—Reply

Author Affiliations

Author Affiliations: Cedars-Sinai Heart Institute, Los Angeles, California (eduardo.marban@csmc.edu).

JAMA. 2013;309(14):1459-1460. doi:10.1001/jama.2013.2604

In Reply: Our Editorial addressed the prevailing confusion in the literature regarding bone marrow–derived cell therapy for heart disease, confusion which was only compounded by the CCTRN's TIME trial.1

First, while the general principle of bone marrow MNC isolation is the same for the manual and automated systems (density gradient-based separation), small details in methods of cell manufacturing can yield cells of different potency.2